Michel Attal

47.9k total citations · 5 hit papers
322 papers, 16.2k citations indexed

About

Michel Attal is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Michel Attal has authored 322 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 269 papers in Hematology, 148 papers in Oncology and 131 papers in Molecular Biology. Recurrent topics in Michel Attal's work include Multiple Myeloma Research and Treatments (212 papers), Protein Degradation and Inhibitors (75 papers) and Cancer Treatment and Pharmacology (69 papers). Michel Attal is often cited by papers focused on Multiple Myeloma Research and Treatments (212 papers), Protein Degradation and Inhibitors (75 papers) and Cancer Treatment and Pharmacology (69 papers). Michel Attal collaborates with scholars based in France, United States and Italy. Michel Attal's co-authors include Thierry Façon, Philippe Moreau, Jean‐Luc Harousseau, Hervé Avet‐Loiseau, Gérald Marit, Norbert Ifrah, Jean Roy, Denis Caillot, Catherine Payen and Philippe Casassus and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Michel Attal

314 papers receiving 15.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

1996 2.0k citations Michel Attal, Thierry Façon et al. profile →
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

2003 699 citations Michel Attal, Thierry Façon et al. profile →
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2017 518 citations Philippe Moreau, Pieter Sonneveld et al. Annals of Oncology profile →
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017 392 citations Philip L. McCarthy, Sarah A. Holstein et al. Journal of Clinical Oncology profile →
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

2020 233 citations Michel Attal, Philippe Moreau et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michel Attal

Since Specialization

Citations

This map shows the geographic impact of Michel Attal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Attal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Attal more than expected).

Fields of papers citing papers by Michel Attal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Attal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Attal. The network helps show where Michel Attal may publish in the future.

Co-authorship network of co-authors of Michel Attal

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Attal. A scholar is included among the top collaborators of Michel Attal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Attal. Michel Attal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study 2018 ·Clinical Cancer Research ·Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugène, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Façon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber‐Bodéré, Caroline Bodet‐Milin	20
2	Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation 2017 ·Blood ·Leon Furchtgott, Arnold Bolomsky, Fred K. Gruber, Mehmet Samur, Jonathan J. Keats, (unknown), (unknown), Michel Attal, Philippe Moreau, Hervé Avet‐Loiseau, (unknown), Diane Wuest, Kelly Rich, Iya Khalil, Boris Hayete, Heinz Ludwig, Nikhil Munshi, Daniel Auclair	2
3	Expressed fusion gene landscape and its impact in multiple myeloma 2017 ·Nature Communications ·Alice Cleynen, Raphaël Szalat, Mehmet Samur, (unknown), Laure Buisson, (unknown), Marie‐Lorraine Chrétien, Kenneth C. Anderson, Stéphane Minvielle, Philippe Moreau, Michel Attal, Giovanni Parmigiani, Jill Corre, Nikhil C. Munshi, Hervé Avet‐Loiseau	25
4	Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against 2017 ·Expert Opinion on Pharmacotherapy ·Paul G. Richardson, Sarah A. Holstein, Robert Schlossman, Kenneth C. Anderson, Michel Attal, Philip L. McCarthy	8
5	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma 2016 ·Clinical Cancer Research ·Florence Magrangeas, Rowan Kuiper, Hervé Avet‐Loiseau, Wilfried Gouraud, Catherine Guérin‐Charbonnel, Ludovic Ferrer, Alexandre Aussem, Haytham Elghazel, (unknown), (unknown), Michel Attal, Nikhil C. Munshi, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, L. Campion, Stéphane Minvielle	30
6	Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 2013 ·Journal of Clinical Oncology ·Pieter Sonneveld, Hartmut Goldschmidt, Laura Rosiñol, Joan Bladé, Juan José Lahuerta, Michèle Cavo, Paola Tacchetti, Elena Zamagni, Michel Attal, Henk M. Lokhorst, Avinash Desai, Andrew Cakana, Kevin Liu, Helgi van de Velde, Dixie‐Lee Esseltine, Philippe Moreau	150
7	Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma 2012 ·Cancer Research ·Jill Corre, (unknown), Nicolas Espagnolle, Benjamin Hébraud, Hervé Avet‐Loiseau, Murielle Roussel, Anne Huynh, Mélanie Gadelorge, Pierre Cordelier, Bernard Klein, Philippe Moreau, Thierry Façon, Jean‐Jacques Fournié, Michel Attal, Philippe Bourin	76
8	Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT) 2011 ·Annals of Oncology ·Esa Jantunen, (unknown), Michel Attal, Kirsty Thomson, Nöel Milpied, Agnès Buzyn, A Ferrant, Pierre Biron, Charles Crawley, A Schattenberg, J.J. Luan, Hervé Tilly, Bernard Rio, P. Wijermans, Peter Dreger, Anna Sureda	35
9	Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? 2010 ·Blood ·Hervé Avet‐Loiseau, Florent Malard, L. Campion, Florence Magrangeas, Catherine Sebban, Bruno Lioure, Olivier Decaux, Thierry Lamy, Laurence Legros, Jean‐Gabriel Fuzibet, Mauricette Michallet, Bernadette Corront, Pascal Lenain, Cyrille Hulin, Claire Mathiot, Michel Attal, Thierry Façon, Jean‐Luc Harousseau, Stéphane Minvielle, Philippe Moreau, (unknown)	92
10	Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences 2010 ·Journal of Clinical Oncology ·Bart Barlogie, Michel Attal, John Crowley, Frits van Rhee, Jackie Szymonifka, Philippe Moreau, Brian G.M. Durie, Jean‐Luc Harousseau	103
11	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) 2010 ·Journal of Clinical Oncology ·Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Philippe Moreau, Catherine Guérin‐Charbonnel, Denis Caillot, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Claire Mathiot, Brigitte Kolb, Margaret Macro, L. Campion, Marc Wetterwald, Anne‐Marie Stoppa, Cyrille Hulin, Thierry Façon, Michel Attal, Stéphane Minvielle, Jean‐Luc Harousseau	298
12	The role of complete response in multiple myeloma 2009 ·Blood ·Jean‐Luc Harousseau, Michel Attal, Hervé Avet‐Loiseau	148
13	The Role of High-Dose Therapy With Autologous Stem Cell Support in the Era of Novel Agents 2009 ·Seminars in Hematology ·Michel Attal, Jean‐Luc Harousseau	13
14	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure 2008 ·Blood ·Michael Wang, Meletios Α. Dimopoulos, Christine Chen, María Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert Knight, Donna M. Weber	135
15	Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome 2008 ·Journal of Clinical Oncology ·Olivier Decaux, Laurence Lodé, Florence Magrangeas, Catherine Guérin‐Charbonnel, Wilfried Gouraud, Pascal Jézéquel, Michel Attal, Jean‐Luc Harousseau, Philippe Moreau, Régis Bataille, L. Campion, Hervé Avet‐Loiseau, Stéphane Minvielle	269
16	Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire 2008 ·Journal of Clinical Oncology ·Steven Le Gouill, Nöel Milpied, Agnès Buzyn, Régis Peffault de Latour, Jean‐Paul Vernant, Mohamad Mohty, Marie‐Pierre Moles, Krimo Bouabdallah, Claude‐Eric Bulabois, Jehan Dupuis, Bernard Rio, N Gratecos, Ibrahim Yakoub‐Agha, Michel Attal, Olivier Tournilhac, Didier Decaudin, (unknown), Didier Blaise, Christelle Volteau, Mauricette Michallet	208
17	The Interpretation of a Treaty by a National Jurisdiction 2007 ·Toulouse Capitole Publications (University Toulouse 1 Capitole) ·Michel Attal	1
18	The Future Role of Thalidomide in Multiple Myeloma 2005 ·Acta Haematologica ·Mario Boccadoro, Joan Bladé, Michel Attal, Antonio Palumbo	2
19	STANDARD THERAPY VERSUS AUTOLOGOUS TRANSPLANTATION IN MULTIPLE MYELOMA 1997 ·Hematology/Oncology Clinics of North America ·Michel Attal, Jean‐Luc Harousseau	34
20	Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. 1995 ·PubMed ·Harousseau Jl, Michel Attal, Marine Diviné, Nöel Milpied, Gérald Marit, (unknown), Stoppa Am, (unknown), Denis Caillot, M Boasson	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact